IP Library Granted Patent US 12673922
Granted Patent B1
US 12673922 · App. 19/395,521 · Granted Jul 7, 2026

5-(3-bromophenyl)-3-((diethylamino)methyl)-5-methylimidazolidine-2,4-dioneas

Inventors: Yousef Saad Yousef Aldabayan (Al-Ahsa, SA); Hany Mohamed Abd El-Lateef Ahmed (Al-Ahsa, SA)
Assignee: KING FAISAL UNIVERSITY
C07D233/76A61K31/417A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673922
App. No.
19/395,521
Granted
Jul 7, 2026
Kind
B1
Abstract

A compound 5-(3-bromophenyl)-3-((diethylamino)methyl)-5-methylimidazolidine-2,4-dione, its synthesis, use as an antibacterial agent and an inhibitor of Chronic Obstructive Pulmonary Disease (COPD).

Claims (6)

1 . A method of treating a bacterial infection in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a 5-(3-bromophenyl)-3-((diethylamino)methyl)-5-methylimidazolidine-2,4-dione compound of formula 1 and a pharmaceutically acceptable carrier:

2 . The method of treating the bacterial infection of claim 1 , wherein the bacterial infection is caused by one or more bacteria.

3 . The method of treating the bacterial infection of claim 2 , wherein the bacterial infection is caused by at least one of a gram positive bacteria, a gram negative bacteria, and a combination thereof.

4 . The method of treating the bacterial infection of claim 3 , wherein the gram positive bacteria is selected from the group consisting of Bacillus cereus, Staphylococcus aureus , and a combination thereof.

5 . The method of treating the bacterial infection of claim 3 , wherein the gram negative bacteria is selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli , and a combination thereof.

6 . A method of treating chronic obstructive pulmonary disease (COPD) inhibition in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a 5-(3-bromophenyl)-3-((diethylamino)methyl)-5-methylimidazolidine-2,4-dione compound of formula 1 and a pharmaceutically acceptable carrier: